SUPN in the 13F filings
Supernus Pharmaceuticals Inc · CUSIP 868459108
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 15 May 2024
- latest of these filings; the earliest 13 May 2024
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 1 listed it in both
- Shares listed
- 2,673,543
- combined, among listed positions
- Reported value
- $91m
- combined, at the quarter end
Among the 93 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +1,295,121.
Managers listing SUPN in Q1 2024
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | 1,333,222 | $45m | 0.07% | Trimmed | -45,200 | 13 May 2024 (the filing on sec.gov) |
| Woodline Partners LP | 1,291,291 | $44m | 0.41% | New | new | 15 May 2024 (the filing on sec.gov) |
| PDT Partners LLC | 49,030 | $1.7m | 0.16% | New | new | 15 May 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Woodline Partners LPnew position · 1,291,291 shares now+1,291,291
- PDT Partners LLCnew position · 49,030 shares now+49,030
Reductions
- Renaissance Technologies LLCexisting position · 1,333,222 shares now-45,200
New positions and exits
New (2)
- Woodline Partners LP$44m
- PDT Partners LLC$1.7m
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2014 | 1 | $1.1m | n.a. | n.a. |
| Q1 2015 | 1 | $1.3m | n.a. | n.a. |
| Q2 2015 | 2 | $10m | n.a. | n.a. |
| Q3 2015 | 1 | $10m | n.a. | n.a. |
| Q4 2015 | 2 | $23m | n.a. | n.a. |
| Q1 2016 | 3 | $38m | n.a. | n.a. |
| Q2 2016 | 2 | $33m | n.a. | n.a. |
| Q3 2016 | 1 | $43m | n.a. | n.a. |
| Q4 2016 | 1 | $42m | n.a. | n.a. |
| Q1 2017 | 1 | $51m | n.a. | n.a. |
| Q2 2017 | 2 | $68m | n.a. | n.a. |
| Q3 2017 | 3 | $53m | n.a. | n.a. |
| Q4 2017 | 1 | $51m | n.a. | n.a. |
| Q1 2018 | 5 | $70m | n.a. | n.a. |
| Q2 2018 | 3 | $122m | n.a. | n.a. |
| Q3 2018 | 2 | $45m | n.a. | n.a. |
| Q4 2018 | 5 | $50m | n.a. | n.a. |
| Q1 2019 | 5 | $61m | n.a. | n.a. |
| Q2 2019 | 6 | $54m | n.a. | n.a. |
| Q3 2019 | 3 | $46m | n.a. | n.a. |
| Q4 2019 | 6 | $28m | n.a. | n.a. |
| Q1 2020 | 7 | $29m | n.a. | n.a. |
| Q2 2020 | 4 | $33m | n.a. | n.a. |
| Q3 2020 | 3 | $49m | n.a. | n.a. |
| Q4 2020 | 1 | $47m | n.a. | n.a. |
| Q1 2021 | 1 | $46m | n.a. | n.a. |
| Q2 2021 | 2 | $48m | n.a. | n.a. |
| Q3 2021 | 3 | $40m | n.a. | n.a. |
| Q4 2021 | 2 | $36m | n.a. | n.a. |
| Q1 2022 | 4 | $62m | n.a. | n.a. |
| Q2 2022 | 4 | $62m | n.a. | n.a. |
| Q3 2022 | 5 | $75m | n.a. | n.a. |
| Q4 2022 | 5 | $53m | n.a. | n.a. |
| Q1 2023 | 3 | $55m | n.a. | n.a. |
| Q2 2023 | 2 | $45m | n.a. | n.a. |
| Q3 2023 | 1 | $40m | n.a. | n.a. |
| Q4 2023 | 1 | $40m | 0 | 1 |
| Q1 2024 | 3 | $91m | 2 | 1 |
| Q2 2024 | 1 | $45m | 1 | 2 |
| Q3 2024 | 3 | $61m | 3 | 0 |
| Q4 2024 | 3 | $75m | 2 | 1 |
| Q1 2025 | 3 | $54m | 1 | 2 |
| Q2 2025 | 3 | $80m | 3 | 0 |
| Q3 2025 | 6 | $244m | 5 | 1 |
| Q4 2025 | 9 | $381m | 17 | 14 |
| Q1 2026 | 8 | $399m | 17 | 15 |
| Q2 2026 | 6 | $299m | 15 | 16 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
SUPN and LLY →SUPN and JNJ →SUPN and VRTX →Choose a stock to compare with SUPN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own SUPN, latest filings →Back to the 13F Explorer →